[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-350218-105":59,"doc-detail-350218-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","mecom-function-is-critical-for-ar-driven-treatment-resistant-prostate-cancer","MECOM Function Is Critical for AR-Driven Treatment-Resistant Prostate Cancer","","Reprogramming of the androgen receptor (AR) cistrome is linked to prostate cancer progression, especially advanced castration-resistant prostate cancer (CRPC) that continues noncanonical AR signaling under AR signaling inhibitors. The study identifies MECOM, encoding the oncogenic transcription factor EVI1, as an AR-recruited coactivator of this noncanonical signaling. In CRPC, MECOM is overexpressed and nuclear-bound with AR, and MECOM depletion reduces proliferation, shifts survival transcriptional programs, and lowers super-enhancers.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/mecom-function-is-critical-for-ar-driven-treatment-resistant-prostate-cancer/350218/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/mecom-function-is-critical-for-ar-driven-treatment-resistant-prostate-cancer/350218.png","ImageObject",300,407,{"name":92,"@type":93},"วิน","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-16","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What does the study conclude about MECOM in AR-driven treatment-resistant CRPC?","Question",{"text":112,"@type":113},"MECOM acts as a driver of androgen receptor inhibitor resistance in castrate-resistant prostate cancer by promoting susceptibility to PARP inhibition.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How is EVI1 related to MECOM and noncanonical AR signaling?",{"text":117,"@type":113},"EVI1 is an oncogenic nuclear transcription factor encoded by MECOM and functions as an AR-recruited coactivator of noncanonical AR signaling.",{"name":119,"@type":110,"acceptedAnswer":120},"Why are MECOM/EVI1-overexpressing cells important for PARP inhibitor response?",{"text":121,"@type":113},"Cells overexpressing MECOM and EVI1 are susceptible to PARP inhibitors regardless of DNA damage response or homologous recombination repair mutation status.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},350218,1790154726,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},2336475104736,"https://ap-avatar.wpscdn.com/avatar/22000c4c5e0e5b17e70?x-image-process=image/resize,m_fixed,w_180,h_180&k=1786591360781797222","MECOM Function Is Critical for AR-Driven Treatment-Resistant Prostate Cancer  \nSurendra Gulla1, Tej Sharma1, Ephraim Gardner1,2, Chennan Li3, Tanaya A. Purohit4, Chao Xue5, Sean Colligan1, Shreya Shyam Sundar1,2, Bing Yang4, Shana Y. Trostel3, Brian Capaldo6, Jonathan E. Bard7,8, Tobilola Ogunbowale1, Abbas Jawadwala1,2, Min Ma9, Jun Qu9, Fatima Karzai3, Roberto Pili1,2,10, David F. Jarrard4, Adam G. Sowalsky3, David J. VanderWeele11,12,  \nand Remi Adelaiye-Ogala1,2,8,10  \n|  |  | A |  | B | S |  | T | R |  | A |  | C | T |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n|  | Reprogramming of the androgen receptor (AR) cistrome is associated with prostate cancer progression, and advanced castration-resistant prostate cancers (CRPC) tend to rely on reprogrammed/noncanonical AR signaling that remains active under treatment with AR signaling inhibitors (ARSI). In this study, we identified ecotropic viral integration site 1 (EVI1), anoncogenic nuclear transcription factor (TF) encoded by MECOM, as an AR-recruited coactivator of noncanonical signaling. In prostate cancer, MECOM was exclusively overexpressed in both CRPC and enzalutamide-resistant CRPC and interacted with AR in the nucleus. MECOM depletion in prostate cancer cells decreased proliferation, altered cell survival transcriptional programs, and reduced the number of super-enhancers (SE), leading to a dynamic change in the SE landscape and a decrease in the expression of SE-regulated oncogenic TFs, along with increased proapoptotic signatures. Notably, cells overexpressing MECOM and its protein, EVI1, were susceptible to PARP inhibitors (PARPi) regardless of their DNA damage response or homologous recombination repair (HRR) gene mutation status. These insights reveal the crucial role of EVI1 in regulating cell survival within the context of an AR-reprogrammed chromatin landscape. More importantly, the findings suggest that MECOM overexpression\u003Cbr>􀀶 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | may be another biomarker that could significantly broaden the use of PARPis beyond those with HRR gene mutations.\u003Cbr>Significance: MECOM is a driver of androgen receptor inhibitor resistance in castrate-resistant prostate cancer that promotes susceptibility to PARP inhibition, positioning MECOM asa biomarker in patients without homologous recombination repair gene mutations.\u003Cbr>|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |\n\nIntroduction  \nIn the past decade, novel hormonal therapy for advanced prostate cancer has gained increasing recognition for improving metastasisfree and overall survival. Nonetheless, acquired resistance to nextgeneration agents targeting the androgen receptor (AR) continues to evolve, characterized by consistent reprogramming of the AR cistrome that activates novel gene signatures and biological processes  \n1Division of Hematology and Oncology, Department of Medicine, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, New York. 2Depar","cbCaipSqaHHrYXMz","https://ap.wps.com/l/cbCaipSqaHHrYXMz","pdf",23096466,18,"English","# Introduction\n## Background on hormonal therapy and AR resistance\n## Role of AR reprogramming and coactivators","[{\"question\":\"What does the study conclude about MECOM in AR-driven treatment-resistant CRPC?\",\"answer\":\"MECOM acts as a driver of androgen receptor inhibitor resistance in castrate-resistant prostate cancer by promoting susceptibility to PARP inhibition.\"},{\"question\":\"How is EVI1 related to MECOM and noncanonical AR signaling?\",\"answer\":\"EVI1 is an oncogenic nuclear transcription factor encoded by MECOM and functions as an AR-recruited coactivator of noncanonical AR signaling.\"},{\"question\":\"Why are MECOM/EVI1-overexpressing cells important for PARP inhibitor response?\",\"answer\":\"Cells overexpressing MECOM and EVI1 are susceptible to PARP inhibitors regardless of DNA damage response or homologous recombination repair mutation status.\"}]","MECOM Function Is Critical for AR-Driven Treatment-Resistant Prostate Cancer | PDF",1790087842,45,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7792c69de5546de1c59536f1797d796b.webp",983,1315,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2a8f2a56bfdb77a465fcb0facb8b05a8.webp",982,1314,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f8492461a69831c1feda08bb02ba79d5.webp",981,1312,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f29fe3048da2cb77a982ac03e46fae11.webp",980,1311]